Phase II failures: 2008–2010
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the decreasing success rate of drugs entering clinical trials (29) suggests that the pharmacology of target-based drug candidates predicts their therapeutic efficacy and toxicity poorly.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [29]
In the citing paper
“In the development of pharmaceutical drugs over 80% fail to reach ‘Phase III’ effectiveness trials, even after considerable investment [4].”
From Exploratory studies to decide whether and how to proceed with full-scale evaluations of public health interventions: a systematic review of guidance (2018) · cites this paper as [4]
Citations
Cites
Still being checked.
Cited by
Items 101–200 of 624
Takahashi, N., Hoshi, H., Higa, A., Hiyama, G., Tamura, H., Ogawa, M., Takagi, K., Goda, K., Okabe, N., Muto, S., et al. (2019) · Cells · doi:10.3390/cells8050481 · Cited by 80
An effector index to predict target genes at GWAS loci
Forgetta, V., Jiang, L., Vulpescu, N. A., Hogan, M. S., Chen, S., Morris, J. A., Grinek, S., Benner, C., Jang, D., Hoang, Q., et al. (2022) · Human Genetics · doi:10.1007/s00439-022-02434-z · Cited by 79
Guo, D. M., Heitman, L. H., & IJzerman, A. P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00025 · Cited by 86
Authorization of Animal Experiments Is Based on Confidence Rather than Evidence of Scientific Rigor
Vogt, L., Reichlin, T. S., Nathues, C., & Würbel, H. (2016) · PLOS Biology · doi:10.1371/journal.pbio.2000598 · Cited by 73
Moore, L., Hallingberg, B., Wight, D., Turley, R., Segrott, J., Craig, P., Robling, M. R., Murphy, S., Simpson, S. A., & Moore, G. F. (2018) · Journal of Epidemiology & Community Health · doi:10.1136/jech-2017-210414 · Cited by 74
Maximizing the impact of microphysiological systems with in vitro – in vivo translation
Cirit, M., & Stokes, C. L. (2018) · Lab on a Chip · doi:10.1039/c8lc00039e · Cited by 72
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy
Ianevski, A., Kononov, A., Timonen, S., Aittokallio, T. A., & Giri, A. K. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007604 · Cited by 72
The impact of CRISPR–Cas9 on target identification and validation
Moore, J. D. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.016 · Cited by 81
Pun, N. T., & Jeong, C. (2021) · Pharmaceuticals · doi:10.3390/ph14050470 · Cited by 81
Mendelian randomisation applied to drug development in cardiovascular disease: a review
Mokry, L. E., Ahmad, O. S., Forgetta, V., Thanassoulis, G., & Richards, J. B. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102438 · Cited by 70
Model-based drug discovery: implementation and impact
Visser, S. A. G., Aurell, M., Jones, R. D. O., Schuck, V., Egnell, A., Peters, S. A., Brynne, L., Yates, J. W. T., Jansson‐Löfmark, R., Tan, B., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.012 · Cited by 70
Ho, H. K., Yeo, A. H. L., Kang, T. S., & Chua, B. T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.021 · Cited by 67
The right compound in the right assay at the right time: an integrated discovery DMPK strategy
Ballard, P. G., Brassil, P. J., Bui, K., Dolgos, H., Petersson, C., Tunek, A., & Webborn, P. J. H. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.691099 · Cited by 64
Walley, R. J., Smith, C. L., Gale, J. D., & Woodward, P. (2015) · Pharmaceutical Statistics · doi:10.1002/pst.1675 · Cited by 67
Bringing together the academic drug discovery community
Slusher, B. S., Conn, P. J., Frye, S. V., Glicksman, M. A., & Arkin, M. R. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4155 · Cited by 61
Defining and characterizing drug/compound function
Kenakin, T., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.033 · Cited by 69
Redford, K. H., Brooks, T. M., MacFarlane, N., & Adams, J. S. (2019) · doi:10.2305/iucn.ch.2019.05.en · Cited by 78
Genovese, L., Zawada, L., Tosoni, A., Ferri, A., Zerbi, P., Allevi, R., Nebuloni, M., & Alfano, M. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0588 · Cited by 59
Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules
Luker, T. J., Alcaraz, L., Chohan, K. K., Blomberg, N., Brown, D. S., Butlin, R. J., Elebring, T., Griffin, A. M., Guile, S. D., St-Gallay, S. A., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.07.074 · Cited by 60
Key indicators of phase transition for clinical trials through machine learning
Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S., & Albright, T. E. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.014 · Cited by 58
Landeck, L., Kneip, C., Reischl, J., & Asadullah, K. (2016) · Experimental Dermatology · doi:10.1111/exd.12948 · Cited by 67
Functional assessments in repeat-dose toxicity studies: the art of the possible
Redfern, W. S., Ewart, L. C., Lainée, P., Pinches, M., Robinson, S., & Valentin, J. (2013) · Toxicology Research · doi:10.1039/c3tx20093k · Cited by 57
Kornegay, J. N., Spurney, C. F., Nghiem, P. P., Brinkmeyer‐Langford, C., Hoffman, E. P., & Nagaraju, K. (2014) · ILAR Journal · doi:10.1093/ilar/ilu011 · Cited by 67
Sundstrøm, T., Daphu, I., WENDELBO, I. H., Hodneland, E., Lundervold, A., Immervoll, H., Skaftnesmo, K. O., Babič, M., Jendelová, P., Syková, E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3514 · Cited by 54
Tagle, D. A. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.007 · Cited by 68
Voitsitskyi, T., Stratiichuk, R., Koleiev, I., Popryho, L., Ostrovsky, Z., Henitsoi, P., Khropachov, I., Vozniak, V., Zhytar, R., Nechepurenko, D., et al. (2023) · RSC Advances · doi:10.1039/d3ra00281k · Cited by 57
Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms
García-Serna, R., Vidal, D., Remez, N., & Mestres, J. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00260 · Cited by 56
Tian, L., Gao, J., Garcia, I. M., Chen, H. J., Castaldi, A., & Chen, Y. (2020) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.399 · Cited by 58
An industry perspective on the role and utility of animal models of pain in drug discovery
Whiteside, G. T., Pomonis, J. D., & Kennedy, J. D. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.08.033 · Cited by 59
Schuck, E. L., Bohnert, T., Chakravarty, A., Damian‐Iordache, V., Gibson, C. R., Hsu, C., Heimbach, T., Krishnatry, A. S., Liederer, B. M., Jing, L., et al. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9716-2 · Cited by 54
Sanoh, S., Naritomi, Y., Fujimoto, M., Sato, K., Kawamura, A., Horiguchi, A., Sugihara, K., Kotake, Y., Ohshita, H., Tateno, C., et al. (2015) · Xenobiotica · doi:10.3109/00498254.2015.1007112 · Cited by 55
Bailey, J., & Balls, M. (2019) · BMC Medical Ethics · doi:10.1186/s12910-019-0352-3 · Cited by 51
Fauzi, F. M., Koutsoukas, A., Lowe, R., Joshi, K., Fan, T., Glen, R. C., & Bender, A. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci3005513 · Cited by 51
Tamura, H., Higa, A., Hoshi, H., Hiyama, G., Takahashi, N., Ryufuku, M., Morisawa, G., Yanagisawa, Y., Ito, E., Imai, J., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6501 · Cited by 54
Validating ADME QSAR Models Using Marketed Drugs
Siramshetty, V. B., Williams, J., Nguyễn, Ð.-T., Neyra, J., Southall, N. T., Mathé, E. A., Xu, X., & Shah, P. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211017520 · Cited by 67
Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development
Hargrove-Grimes, P., Low, L. A., & Tagle, D. A. (2021) · Cells Tissues Organs · doi:10.1159/000517422 · Cited by 62
Academic drug discovery: current status and prospects
Everett, J. R. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1059816 · Cited by 53
Hallmarks of therapeutic management of the cystic fibrosis functional landscape
Amaral, M. D., & Balch, W. E. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.09.006 · Cited by 52
Use of Humanized Mice to Study the Pathogenesis of Autoimmune and Inflammatory Diseases
Koboziev, I., Jones‐Hall, Y., Valentine, J. F., Webb, C. R., Furr, K. L., & Grisham, M. B. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000446 · Cited by 56
Disease models for the development of therapies for lysosomal storage diseases
Xu, M., Motabar, O., Ferrer, M., Marugán, J., Zheng, W., & Ottinger, E. A. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13052 · Cited by 54
Subbotin, V. M. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.017 · Cited by 59
Waltemath, D., & Wolkenhauer, O. (2016) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2555481 · Cited by 49
Predictive biomarkers in precision medicine and drug development against lung cancer
Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015) · 癌症:英文版 · doi:10.1186/s40880-015-0028-4 · Cited by 52
Green, S. B. (2015) · BMC Medical Ethics · doi:10.1186/s12910-015-0043-7 · Cited by 53
A call to reform the taxonomy of human disease
Kola, I., & Bell, J. I. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3534 · Cited by 48
A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?
Beach, T. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0072-x · Cited by 56
Walker, L. C., Berizzi, A. E., Chen, N. A., Rueda, P., Perreau, V. M., Huckstep, K., Srisontiyakul, J., Govitrapong, P., Jia, X., Lindsley, C. W., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.019 · Cited by 49
Krafczyk, M. S., Shi, A., Bhaskar, A., Marinov, D., & Stodden, V. (2021) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2020.0069 · Cited by 61
Molecular interaction fields in drug discovery: recent advances and future perspectives
Artese, A., Cross, S., Costa, G., Distinto, S., Parrotta, L., Alcaro, S., Ortuso, F., & Cruciani, G. (2013) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1150 · Cited by 50
Drug Repurposing for the Development of Novel Analgesics
Sisignano, M., Parnham, M. J., & Geißlinger, G. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.006 · Cited by 52
Zielinski, D. C., Filipp, F. V., Bordbar, A., Jensen, K., Smith, J. W., Herrgard, M. J., Mo, M. L., & Palsson, B. O. (2015) · Nature Communications · doi:10.1038/ncomms8101 · Cited by 46
Kenakin, T. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13217 · Cited by 45
Does Targeted, Disease‐Specific Public Research Funding Influence Pharmaceutical Innovation?
Blume‐Kohout, M. E. (2012) · Journal of Policy Analysis and Management · doi:10.1002/pam.21640 · Cited by 51
Challenges and opportunities for oncology biomarker discovery
Deyati, A., Younesi, E., Hofmann‐Apitius, M., & Novac, N. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.12.011 · Cited by 53
Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates
Schou, M., Varnäs, K., Lundquist, S., Nakao, R., Amini, N., Takano, A., Finnema, S. J., Halldin, C., & Farde, L. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv036 · Cited by 45
Use of Baculovirus BacMam Vectors for Expression of ABC Drug Transporters in Mammalian Cells
Shukla, S., Schwartz, C., Kapoor, K., Kouanda, A. M., & Ambudkar, S. V. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042721 · Cited by 47
Chamberlain, C. E., German, M. S., Yang, K. Y., Wang, J., VanBrocklin, H. F., Regan, M., Shokat, K. M., Ducker, G. S., Kim, G., Hann, B. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1204 · Cited by 45
Ikari, R., Mukaisho, K., Kageyama, S., Nagasawa, M., Kubota, S., Nakayama, T., Murakami, S., Taniura, N., Tanaka, H., Kushima, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041805 · Cited by 49
Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types
Engle, S. J., & Vincent, F. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.529156 · Cited by 55
From protein interaction networks to novel therapeutic strategies
Jaeger, S., & Aloy, P. (2012) · IUBMB Life · doi:10.1002/iub.1040 · Cited by 50
Arendt‐Nielsen, L., Harris, S., Whiteside, G. T., Hummel, M., Knappenberger, T., OʼKeefe, S. A., Kapil, R. P., & Kyle, D. J. (2016) · Pain · doi:10.1097/j.pain.0000000000000610 · Cited by 44
Huang, R., Xia, M., Sakamuru, S., Zhao, J., Lynch, C., Zhao, T., Zhu, H., Austin, C. P., & Simeonov, A. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22046-w · Cited by 50
A Mechanistic, Model‐Based Approach to Safety Assessment in Clinical Development
Lippert, J., Brosch, M., von Kampen, O., Meyer, M., Siegmund, H. ‐., Schafmayer, C., Becker, T., Laffert, B., Görlitz, L., Schreiber, S., et al. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.14 · Cited by 43
Multi-arm clinical trials with treatment selection: what can be gained and at what price?
Jaki, T. (2015) · Clinical Investigation · doi:10.4155/cli.15.13 · Cited by 49
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
Ianevski, A., Lahtela, J., Javarappa, K. K., Sergeev, P., Ghimire, B. R., Gautam, P., Vähä-Koskela, M. J. V., Turunen, L., Linnavirta, N., Kuusanmäki, H. A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe4038 · Cited by 43
Bretherick, A. D., Canela-Xandri, O., Joshi, P. K., Clark, D. W., Rawlik, K., Boutin, T. S., Zeng, Y., Amador, C., Navarro, P., Rudan, I., et al. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1008785 · Cited by 42
Brundin, P., Barker, R. A., Conn, P. J., Dawson, T. M., Kieburtz, K. D., Lees, A. J., Schwarzschild, M. A., Tanner, C. M., Isaacs, T., Duffen, J., et al. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-139000 · Cited by 43
Animal models of hospital-acquired pneumonia: current practices and future perspectives
Bielen, K., Jongers, B. ‘., Malhotra‐Kumar, S., Jorens, P. G., Goossens, H., & Kumar‐Singh, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.72 · Cited by 48
Analyzing crowdsourced ratings of speech-based take-over requests for automated driving
Bazilinskyy, P., & de Winter, J. (2017) · Applied Ergonomics · doi:10.1016/j.apergo.2017.05.001 · Cited by 53
Varesano, S., Zocchi, M. R., & Poggi, A. D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00998 · Cited by 45
Driving success in personalized medicine through AI-enabled computational modeling
Chakravarty, K., Antontsev, V. G., Bundey, Y., & Varshney, J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.007 · Cited by 48
Azevedo, A. M. O., Costa, S. P. F., Dias, A. F., Marques, A. H. O., Pinto, P. C. A. G., Bica, K., Ressmann, A. K., Passos, M. L. C., Araújo, A. R. T. S., Reis, S., et al. (2017) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2017.02.027 · Cited by 45
Tetsuka, K., Ohbuchi, M., & Tabata, K. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.05.010 · Cited by 44
Oja, M., & Maran, U. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.014 · Cited by 46
Badre, D., Frank, M. J., & Moore, C. I. (2015) · Neuron · doi:10.1016/j.neuron.2015.10.021 · Cited by 40
Is Diversity (Un-)Biased? Project Selection Decisions in Executive Committees
Oraiopoulos, N., & Kavadias, S. (2019) · Manufacturing & Service Operations Management · doi:10.1287/msom.2019.0782 · Cited by 42
Li, H., Xiang, Y., Fan, L., Zhang, X., Li, J., Yu, C., Bao, L., Cao, D., Xing, W., Liao, X., et al. (2017) · Gene · doi:10.1016/j.gene.2017.03.029 · Cited by 40
Drug discovery in ophthalmology: past success, present challenges, and future opportunities
Gower, N. J. D., Barry, R. J., Edmunds, M. R., Titcomb, L. C., & Denniston, A. K. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0188-2 · Cited by 41
Sanoh, S., & Ohta, S. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1864 · Cited by 39
Predicting drug–target binding affinity with cross-scale graph contrastive learning
Wang, J., Xiao, Y., Shang, X., & Peng, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad516 · Cited by 59
Engineering brain-on-a-chip platforms
Servais, B., Mahmoudi, N., Gautam, V., Tong, W., Ibbotson, M. R., Nisbet, D. R., & Collins, D. J. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00184-3 · Cited by 50
Tissue chips to aid drug development and modeling for rare diseases
Low, L. A., & Tagle, D. A. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1244479 · Cited by 43
Barker‐Haliski, M. L., Harte‐Hargrove, L. C., Ravizza, T., Smolders, I. J., Xiao, B., Brandt, C., & Löscher, W. (2018) · Epilepsia Open · doi:10.1002/epi4.12254 · Cited by 41
Models of Idiosyncratic Drug-Induced Liver Injury
Yokoi, T., & Oda, S. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-015007 · Cited by 42
Zheng, S., McIntosh, T. S., & Wang, W. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.357 · Cited by 41
Martin, E. S., Belmont, P. J., Sinnamon, M. J., Richard, L. G., Yuan, J., Coffee, E. M., Roper, J., Lee, L., Heidari, P., Lunt, S. Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2307 · Cited by 37
Bdioui, S., Verdi, J., Pierre, N., Trinquet, E., Roux, T., & Kenakin, T. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112573 · Cited by 37
Recent trends in specialty pharma business model
Ku, M. S. (2015) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2015.04.008 · Cited by 52
Hwang, T. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071966 · Cited by 51
In Silico Prediction of Drug-Induced Liver Injury Based on Ensemble Classifier Method
Wang, Y., Xiao, Q., Chen, P., & Wang, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174106 · Cited by 36
The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial
Jamshidi, N., Jonasch, E. W., Zapala, M. A., Korn, R. L., Brooks, J. D., Ljungberg, B., & Kuo, M. (2015) · European Radiology · doi:10.1007/s00330-015-4082-8 · Cited by 36
Lü, H., Iuliano, J. N., & Tonge, P. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.002 · Cited by 39
Seifirad, S., & Haghpanah, V. (2019) · The EPMA Journal · doi:10.1007/s13167-019-00176-z · Cited by 38
CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
Hutson, P. H., Clark, J. A., & Cross, A. J. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104624 · Cited by 40
Developing microphysiological systems for use as regulatory tools – challenges and opportunities
Andersen, M. E., Betts, K., Dragan, Y., Fitzpatrick, S., Goodman, J. L., Hartung, T., Himmelfarb, J., Ingber, D. E., Jacobs, A., Kavlock, R., et al. (2014) · ALTEX · doi:10.14573/altex.1405151 · Cited by 36
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
Roberts, R. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.08.001 · Cited by 35
Greek, R., & Hansen, L. A. (2013) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2013.06.002 · Cited by 36
Würstle, M. L., Zink, E., Prehn, J. H. M., & Rehm, M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.36 · Cited by 38
Low, L. A., Sutherland, M. L., Lumelsky, N. L., Selimović, Š., Lundberg, M. S., & Tagle, D. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36588-2_3 · Cited by 37
Chemical Probes for Understudied Kinases: Challenges and Opportunities
Serafim, R. A. M., Elkins, J. M., Zuercher, W. J., Laufer, S., & Gehringer, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00980 · Cited by 33
Metadata
- Authors
- Arrowsmith, J.
- Affiliations
- Thomson Reuters (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 328-329
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2065540447
- Cited by
- 622
- References
- 0
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 14 · 2022: 21 · 2021: 25 · 2020: 36 · 2019: 44 · 2018: 37 · 2017: 54 · 2016: 64 · 2015: 66 · 2014: 66 · 2013: 88 · 2012: 41
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- drug development failure, clinical trial attrition, drug repurposing, translational research
- MeSH terms
- Drug Industry, Pharmaceutical Preparations, Humans, Drug Design, Treatment Failure, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.